Skip to main content
Clinical Trials/NCT05216419
NCT05216419
Completed
Phase 4

Study for Effectiveness in Prevention of Postoperative Hypocalcemia of Preoperative Oral Supplementation of Vitamin D (D-mac 30,000 IU) in Patients Undergoing Total Thyroidectomy

Seoul National University Hospital2 sites in 1 country108 target enrollmentJune 7, 2021

Overview

Phase
Phase 4
Intervention
Cholecalciferol
Conditions
Total Thyroidectomy
Sponsor
Seoul National University Hospital
Enrollment
108
Locations
2
Primary Endpoint
Postoperative hypocalcemia
Status
Completed
Last Updated
last year

Overview

Brief Summary

The hypocalcemia after total thyroidectomy is one of common surgical complications. It may be asymptomatic, but patients can complain of dysfunction around the mouth or extremities, stiffness or convulsion in severe cases. The incidence of transient hypocalcemia was 6.9-46%, and permanent hypocalcemia was reported to be 0.4-33%. It has been reported that the incidence of hypocalcemia after thyroidectomy is high when the difference in blood levels of parathyroid hormone and vitamin D is large before and after surgery.

Therefore, it is a very important task to study the effect of using vitamin D3 (cholecalciferol), which has a better effect on the human body, on the prevention of hypocalcemia after total thyroidectomy with a long follow-up period after surgery. The department of surgery in Seoul National University Hospital intends to analyze the preventive effect "D-mac 30,000 IU" on postoperative hypocalcemia and safety of 'D-mac 30,000 IU" through a prospective randomized clinical trial.

The incidence of postoperative hypocalcemia of the group taking orally taking vitamin D3 (cholecalciferol) before surgery will be compared with that of the group not taking vitamin D3 before surgery. Patients who are enrolled in this RCT are allocated to the case group and the control group. Patients in the case group are taking 30,000 IU of vitamin D3 (cholecalciferol) orally, and patients in the control group are not taking any drugs.

Primary endpoint of this study is to evaluate the incidence of hypocalcemia. And secondary endpoints are to evaluate the recovery duration from postoperative hypocalcemia and the risk factors for postoperative hypocalcemia.

Registry
clinicaltrials.gov
Start Date
June 7, 2021
End Date
October 16, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Su-jin Kim

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients aged 19 to 70 years old
  • Patients undergoing total thyroidectomy due to thyroid disease
  • Patients who consented to the study and obtained consent for the study

Exclusion Criteria

  • Patients with confirmed hypocalcemia or hypercalcemia before surgery
  • Patients receiving calcium or vitamin D treatment before surgery, patients with excessive vitamin D
  • Patients with a previous history of parathyroid disease or a history of cervical irradiation
  • Patients with confirmed parathyroid comorbidity
  • Patients with diseases or conditions that cause hypercalcemia or hypercalciuria (myeloma, bone metastases, or other malignant bone diseases)
  • Patients with confirmed renal dysfunction (glomerular filtration rate \<60mL/min/1.73m2) before surgery or with a history of chronic renal failure
  • Renal stone disease patient, kidney stone disease patient
  • Patients with bowel disease that may affect serum vitamin D levels (celiac disease, small intestine resorption disease, small bowel resection history)
  • Patients taking drugs that may affect serum calcium or vitamin D levels (anticonvulsants, bisphosphonates, cisplatin, aminoglycosides, diuretics, proton pump inhibitors, glucocorticoid benzodiazepine derivatives, etc.)
  • Uncontrolled hypertension, diabetes, and clotting disorders

Arms & Interventions

case group

One dose of "30,000 IU of D-mac" is taken once 15 days prior to surgery.

Intervention: Cholecalciferol

Outcomes

Primary Outcomes

Postoperative hypocalcemia

Time Frame: postoperative 6 months

The incidence of hypocalcemia at postoperative 6 months

Secondary Outcomes

  • Risk factors for developing postoperative hypocalcemia(1 day, 2 weeks, 3 months, 6 months after surgery)
  • Duration of recovery period from postoperative hypocalcemia(1 day, 2 weeks, 3 months, 6 months after surgery)
  • The occurrence of hypocalcemia sign(1 day, 2 weeks, 3 months, 6 months after surgery)

Study Sites (2)

Loading locations...

Similar Trials